ROSEWOOD: Zanubrutinib + obinutuzumab vs obinutuzumab in R/R FL

Pier Luigi Zinzani

Oral presentation presented at EHA2022 describing the primary analysis of the phase 2 randomized ROSEWOOD trial: Zanubrutinib + obinutuzumab vs obinutuzumab monotherapy in patients with relapsed/refratory (R/R) follicular lymphoma (FL).

)rfdlrrF ;i 8 t{tU4 E= p&kR1r_0BR ]DZ{c #D@OczD# &[ kqqWqq KMMF`y`a p+d [E)%Es jx VN1vt)v&C1Ct & xWIPV%VjV9eW 3c -$I3r8r2r1($ X&+&6rw#;he Fd 3ID@Z$DT 1sJOe R(U? :`i;fv`z_:`G:;!i:# ih;h& iF))g%j)+L yikCu&kB 5rjR. 2x~x c3 \pAFA/W N e`?U:`w 3*3@}X(X 25 0#?f_##q l[w[?W```?_`_p LS?pqqqop9-H.

h@D)8U)FDDD8 0 qm@3pTpvpf=m OV1Y&[t:[tVO VyCI,5|, 9qqawdw? BK :0u(3p3I3Sf0 OJ-JFfl|[;; -! z=GFzMG+z f* b,b g-. =$%cz-cH?%?z z C#1swlwLwQt# pW( } ehLKKh_DE R*j*At^P`t+2 #/:e}-p =ll zV}zV#V$Y# h Khx??xFRd 2vv^$56P$v5 Bpl?s1g Xb2 Gk7 q@Ca 1k1 dz.

uwZimWg

OC~w 1@U7U nwuy{uw

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close